- Home
- FLGT
as 07-26-2024 4:00pm EST
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.
Upcoming Earnings Alert:
Get ready for potential market movements as Fulgent Genetics Inc. FLGT prepares to release earnings report on 02 Aug 2024.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | EL MONTE |
| Market Cap: | 594.6M | IPO Year: | 2016 |
| Target Price: | $30.00 | AVG Volume (30 days): | 219.5K |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.57 | EPS Growth: | N/A |
| 52 Week Low/High: | $18.91 - $44.09 | Next Earning Date: | 08-02-2024 |
| Revenue: | $287,530,000 | Revenue Growth: | -21.20% |
| Revenue Growth (this year): | -1.19% | Revenue Growth (next year): | 14.84% |
Stock Insider Trading Activity of Fulgent Genetics Inc. (FLGT)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Xie Jian | FLGT | President and COO | Dec 11 '23 | Sell | $26.32 | 10,000 | $263,179.00 | 375,124 | SEC Form 4 |
| Xie Jian | FLGT | President and COO | Dec 11 '23 | Sell | $26.69 | 12,000 | $320,274.00 | 363,124 | SEC Form 4 |
| Kim Paul | FLGT | CFO and Treasurer | Dec 4 '23 | Sell | $27.57 | 1,437 | $39,622.69 | 200,460 | SEC Form 4 |
| Xie Jian | FLGT | President and COO | Dec 4 '23 | Sell | $27.57 | 1,779 | $49,052.72 | 385,124 | SEC Form 4 |
| Kim Paul | FLGT | CFO and Treasurer | Nov 16 '23 | Sell | $27.25 | 1,307 | $35,617.19 | 201,897 | SEC Form 4 |
Latest Fulgent Genetics Inc. News
FLGT Breaking Stock News: Dive into FLGT Ticker-Specific Updates for Smart Investing
Argus Research
3 days ago
FLGT: Raising target price to $18.00
Zacks
9 days ago
Fulgent Genetics (FLGT) Soars 6.6%: Is Further Upside Left in the Stock?
Argus Research
10 days ago
HXL: Raising target price to $17.00
Business Wire
15 days ago
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
Argus Research
17 days ago
HXL: What does Argus have to say about FLGT?
Simply Wall St.
a month ago
With 50% ownership, Fulgent Genetics, Inc. (NASDAQ:FLGT) boasts of strong institutional backing
Simply Wall St.
2 months ago
What Is Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Share Price Doing?
Business Wire
2 months ago
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
Compare FLGT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FLGT Fulgent Genetics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.